Cargando…
Molecular evidence and clinical importance of β‐arrestins expression in patients with acromegaly
β‐arrestins seem to have a role in endocytosis and desensitization of somatostatin receptor subtype 2 (sst2) and could be associated with the responsiveness to somatostatin receptor ligands (SRL) in patients with acromegaly. To investigate the in vivo correlation between β‐arrestins 1 and 2 with sst...
Autores principales: | Coelho, Maria Caroline Alves, Vasquez, Marina Lipkin, Wildemberg, Luiz Eduardo, Vázquez‐Borrego, Mari C., Bitana, Luciana, Camacho, Aline Helen da Silva, Silva, Débora, Ogino, Liana Lumi, Ventura, Nina, Chimelli, Leila, Luque, Raul M., Kasuki, Leandro, Gadelha, Mônica R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5867117/ https://www.ncbi.nlm.nih.gov/pubmed/29377493 http://dx.doi.org/10.1111/jcmm.13427 |
Ejemplares similares
-
Clinical significance of filamin A in patients with acromegaly and its association with somatostatin and dopamine receptor profiles
por: Coelho, Maria Caroline Alves, et al.
Publicado: (2019) -
The Future of Somatostatin Receptor Ligands in Acromegaly
por: Gadelha, Monica R, et al.
Publicado: (2021) -
Experience with pegvisomant treatment in acromegaly in a single Brazilian tertiary reference center: efficacy, safety and predictors of response
por: Kasuki, Leandro, et al.
Publicado: (2016) -
miR-383-5p, miR-181a-5p, and miR-181b-5p as Predictors of Response to First-Generation Somatostatin Receptor Ligands in Acromegaly
por: Henriques, Daniel G., et al.
Publicado: (2023) -
gsp Mutation Is Not a Molecular Biomarker of Long-Term Response to First-Generation Somatostatin Receptor Ligands in Acromegaly
por: Wildemberg, Luiz Eduardo, et al.
Publicado: (2021)